BridgeBio Pharma (BBIO) Secured Two Priority Reviews For Rare Disease Drugs
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. BridgeBio Pharma (NasdaqGS:BBIO) reports recent clinical and regulatory milestones across late-stage rare disease assets, including acoramidis, BBP-418, and encaleret. Acoramidis continues to show differentiated …